Published on in Vol 12 (2023)
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/43091, first published
.

Journals
- Chamouard V, Freyssenge J, Duport G, Volot F, Varin R, Giraud N, Dargaud Y, Fraticelli L. Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey. Haemophilia 2023;29(6):1490 View
- Chamouard V, Freyssenge J, Clairaz-Mahiou B, Ferrera Bibas F, Fraticelli L. Evaluation of an e-Learning Program for Community Pharmacists for Dispensing Emicizumab (Hemlibra) in France: Nationwide Cross-Sectional Study. JMIR Formative Research 2024;8:e54656 View
- Cabon M, Chamouard V, Freyssenge J, Fraticelli L. Comparative evaluation of access to emicizumab (Hemlibra®) for people with haemophilia A in community and hospital pharmacies in France. European Journal of Public Health 2024;34(5):866 View
- Liu Y, Peng Y, Zhu B, Xia Z, Yuan Y, Zhang F. Implementing Cancer Pain Management Training for Pharmacists Using the Kirkpatrick Evaluation Model. Journal of Pain Research 2025;Volume 18:305 View
- Leleu H, Fraticelli L, Ajjouri R, Touvron G, Chamouard V. Estimation of the budget impact of the dual dispensing circuit of emicizumab in France: The HemiValue study. Journal of Epidemiology and Population Health 2025;73(2):202975 View
